GH vs LUCD
GH: Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring. LUCD: Lucid Diagnostics develops EsoGuard, the first noninvasive DNA test for early detection of esophageal cancer precursors in millions of chronic GERD patients at risk.
Side-by-side fundamentals
| Metric | GH | LUCD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $150.75 | $0.94 | |
| Market cap as of 2026-07-23 | $19.8B | $192M | |
| PEG as of 2026-07-23 | -71.05 | n/a | |
| Net margin as of 2026-07-23 | -40.1% | -876.7% | GH higher |
| Gross margin as of 2026-07-23 | +64.9% | -31.4% | GH higher |
| Operating margin as of 2026-07-23 | -42.7% | -980.6% | GH higher |
| ROE as of 2026-07-23 | -246.6% | -370.2% | GH higher |
| ROA as of 2026-07-23 | -26.5% | -108.2% | GH higher |
| Debt / equity as of 2026-07-23 | 16.78 | 6.30 | LUCD lower |
| Revenue growth (YoY) as of 2026-07-23 | +39.6% | +23.0% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | +105.6% | LUCD higher |
| Beta as of 2026-07-23 | 1.63 | 1.14 | |
| 1-year return as of 2026-07-22 close | +225.9% | -12.9% | GH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.